Ordinance
|
|
Art. 36 Clinical trials of medicinal products capable of emitting ionising radiation 77
1 For Category B and C clinical trials of medicinal products capable of emitting ionising radiation, the documents specified in Annex 4 number 5 must additionally be submitted to Swissmedic.78 2 In the case of Category C clinical trials, Swissmedic shall seek an opinion from the FOPH before granting approval. The FOPH shall review compliance with radiological protection legislation and the dose estimation.79 3 Swissmedic shall grant approval if:
4 Swissmedic shall reach a decision on Category C clinical trials within 60 days of acknowledgement of receipt of the formally correct application documents. Swissmedic shall inform the FOPH of its decision. 5 …80 77 Amended by No I of the O of 7 June 2024, in force since 1 Nov. 2024 (AS 2024 322). 78 Amended by No I of the O of 7 June 2024, in force since 1 Nov. 2024 (AS 2024 322). 79 Amended by No I of the O of 7 June 2024, in force since 1 Nov. 2024 (AS 2024 322). 80 Repealed by No I of the O of 7 June 2024, with effect from 1 Nov. 2024 (AS 2024 322). |
